Journal: International journal of molecular medicine

Article Title: Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis.

doi: 10.3892/ijmm_00000412

Figure Lengend Snippet: Figure 5. Partial 2D images of liver proteins from obese mice and animals receiving YCHT. The protein levels of SMP30 are shown by Western blotting. The blots are representative of three similar experiments. *P<0.05 compared to the normal diet; #P<0.05 compared to the high fat diet.

Article Snippet: Sixty micrograms of protein was run on a 10% SDS-PAGE gel followed by Western blotting with various mouse or rabbit monoclonal antibodies PPARÁ, SMP30, and Histone H1 from Santa Cruz or anti-actin antibody (Chemicon, USA).

Techniques: Western Blot

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Correlation of low SMP30 level with worse overall survival in NSCLC patients. (A) Representative immunohistochemical (IHC) images for SMP30 expression in NSCLC (lung squamous cell carcinoma and lung adenocarcinoma) and adjacent noncancerous tissues. Scale bar, 200 and 20 µm (inset) respectively. (B) Statistical analysis of SMP30 expression in tumor tissue and adjacent noncancerous tissue of 341 NSCLC patients through IHC staining. (C-F) Kaplan-Meier survival analyses of high/low SMP30 expression based on tissue microarray IHC results for 341 NSCLC patients (C), 1,926 NSCLC patients in the Kaplan-Meier plotter database (D), 1,014 NSCLC patients from The Human Protein Atlas (original RNA-seq data from TCGA) (E), 152 NSCLC patients in the early clinical stages, and 189 NSCLC patients in the late clinical stages (F). (G) Statistical analysis of SMP30 expression in different clinical stages and T classifications of 341 NSCLC patients through IHC staining. SMP30, senescence marker protein 30; NSCLC, non-small cell lung cancer; TCGA, The Cancer Genome Atlas.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Immunohistochemical staining, Expressing, Immunohistochemistry, Microarray, RNA Sequencing, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Association of SMP30 expression with clinicopathologic parameters of patients with NSCLC

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Expressing

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Univariate and multivariate analyses of the correlation between clinicopathological variables for survival of patients with non-small cell lung cancer

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Expressing

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Correlation of low SMP30 level with worse overall survival in both LUAD and LUSC patients. (A,E) Kaplan-Meier survival analyses of high/low SMP30 expression in 719 LUAD patients and 524 LUSC patients, respectively, based on the Kaplan-Meier plotter database. (B-D,F-H) Kaplan-Meier survival analyses of high/low SMP30 expression in 131 LUAD patients and 210 LUSC patients based on the tissue microarray immunohistochemical results. SMP30, senescence marker protein 30; HR, hazard ratio; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Expressing, Microarray, Immunohistochemical staining, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of SMP30 overexpression on proliferative ability of A549 and H1299 cells, and tumor growth in H1299 cell tumor xenografts. (A) Relative protein levels of SMP30 in cell lines as determined by Western blot. β-actin was used as a loading control. (B) Representative Western blot results of Flag, SMP30, c-Myc and CyclinD1 in LV-SMP30 A549 and LV-SMP30 H1299 cells. (C) Growth curves of the A549 and H1299 cells. Cell viability was detected by CCK-8 assay and expressed as optical density values. (D) Representative images and results of the colony formation assay. Colonies were visualized by crystal violet staining. (E) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). (F) Representative results of tumor weight changes after subcutaneous injection of H1299 cells. Photographs show tumor xenograft morphologies in the LV-control and LV-SMP30 H1299 groups. (G) Representative Western blot results of Flag, SMP30, c-Myc and CyclinD1 in H1299 xenograft tumor tissues. β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. LV-control group. LV, lentivirus; SMP30, senescence marker protein 30.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Over Expression, Western Blot, Control, CCK-8 Assay, Colony Assay, Staining, Fluorescence, Injection, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of HDAC4 level of SMP30 overexpression both in vivo and in vitro, and effect of HDAC4 overexpression on NSCLC cell proliferation. (A) Representative Western blot results of HDAC4, HDAC5, HDAC7 and HDAC9 in LV-SMP30 A549 and LV-SMP30 H1299 cells. (B) Representative Western blot results of HDAC4, HDAC5, HDAC7 and HDAC9 in H1299 xenograft tumor tissues. (C) Relative protein levels of HDAC4 in cell lines as determined by Western blot. (D) Representative Western blot results of Flag, HDAC4, c-Myc and CyclinD1 in LV-HDAC4 A549 and LV-HDAC4 H1299 cells. (E) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (F) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. LV-control group. HDAC histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30; SD, standard deviation; NSCLC, non-small cell lung cancer.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Over Expression, In Vivo, In Vitro, Western Blot, Colony Assay, Staining, Fluorescence, Control, Histone Deacetylase Assay, Marker, Standard Deviation

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Essential requirement for HDAC4 in SMP30-mediated NSCLC cell proliferation. (A) Representative Western blot results of Flag, SMP30, HDAC4 and c-Myc and CyclinD1. (B) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (C) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). (D) Representative results for tumor weight changes after subcutaneous injection of H1299 cells. Photographs show tumor xenograft morphologies in the LV-SMP30 + LV-HDAC4 and LV-SMP30 + LV-control H1299 groups. (E) Representative Western blot results of SMP30, HDAC4, c-Myc and CyclinD1 in H1299 xenograft tumor tissues. β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. the LV-SMP30 control group; #, P<0.05 vs. the LV-SMP30 group; &, P<0.05 vs. the LV-SMP30 control + LV-HDAC4 group. HDAC, histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30; SD, standard deviation; NSCLC, non-small cell lung cancer.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Western Blot, Colony Assay, Staining, Fluorescence, Injection, Control, Histone Deacetylase Assay, Marker, Standard Deviation

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of pharmacologic inhibition of HDAC4 on proliferative abilities of H1299 cells. LV-control and LV-HDAC4 H1299 cells were pretreated with SAHA or TMP269 for 48 h. (A,B) Representative Western blot results of HDAC4, c-Myc, and CyclinD1. (C,D) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (E,F) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). *, P<0.05 vs. the LV-control +SAHA/TMP269 0 µM group; #, P<0.05 vs. the LV-control + SAHA1.25 µM/TMP269 40 µM group; &, P<0.05 vs. the LV-HDAC4 + SAHA/TMP269 0 µM group. HDAC, histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30.

Article Snippet: Using paraffin-embedded tissue microarray containing 341 pairs NSCLC and matched adjacent normal lung tissues, IHC staining was conducted using the primary antibodies of anti- SMP30 (1:50, 17947-1-AP, Proteintech), and standard protocols were followed as previously described ( 30 ).

Techniques: Inhibition, Control, Western Blot, Colony Assay, Staining, Fluorescence, Histone Deacetylase Assay, Marker

Journal: Journal of Healthcare Engineering

Article Title: GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma

doi: 10.1155/2022/2518847

Figure Lengend Snippet: Lentiviral vectors: LV5: GP96 lentiviral vector structure; LV8: SMP30 lentiviral vector structure. (a) GP96-transfected DCs. (b) SMP30-transfected DCs. (a) and (b) show the same location.

Article Snippet: We used mouse anti-human HSP90, rabbit anti-human GP96 (Wuhan Boster Biological Technology Ltd.), and mouse anti-human SMP30 (Santa Cruz Biotechnology Inc.) antibodies.

Techniques: Plasmid Preparation, Transfection

Journal: Journal of Healthcare Engineering

Article Title: GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma

doi: 10.1155/2022/2518847

Figure Lengend Snippet: WB after transfection. (a) Detection of GP96 in 6 groups. (b) Detection of SMP30 in 6 groups. (c) GAPDH as the internal control. The GP96 group expressed more GP96, and the SMP30 group expressed more SMP30, indicating that transfection was successful.

Article Snippet: We used mouse anti-human HSP90, rabbit anti-human GP96 (Wuhan Boster Biological Technology Ltd.), and mouse anti-human SMP30 (Santa Cruz Biotechnology Inc.) antibodies.

Techniques: Transfection, Control

Journal: Journal of Healthcare Engineering

Article Title: GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma

doi: 10.1155/2022/2518847

Figure Lengend Snippet: Liver cancer model. (a) The liver cancer model. (b) The GP96 + SMP30 group: tumors had disappeared in some mice on day 4. (c) Tumors harvested from mice. (d) Negative TUNEL staining for apoptosis in the DC group. (e) Positive TUNEL staining for apoptosis in the GP96 + SMP30 group.

Article Snippet: We used mouse anti-human HSP90, rabbit anti-human GP96 (Wuhan Boster Biological Technology Ltd.), and mouse anti-human SMP30 (Santa Cruz Biotechnology Inc.) antibodies.

Techniques: TUNEL Assay, Staining

Journal: Journal of Healthcare Engineering

Article Title: GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma

doi: 10.1155/2022/2518847

Figure Lengend Snippet: Tumor growth curve and ELISA results. Curve: the tumor volume in the GP96 + SMP30 group was smaller than that in the protein group on day 4, day 14, and day 16, P < 0.05. IL-2: the GP96 + SMP30 group showed secretion of more IL-2 than the other groups, P < 0.01. IFN- γ : the GP96 + SMP30 group showed secretion of more IFN- γ than the other groups, P < 0.01.

Article Snippet: We used mouse anti-human HSP90, rabbit anti-human GP96 (Wuhan Boster Biological Technology Ltd.), and mouse anti-human SMP30 (Santa Cruz Biotechnology Inc.) antibodies.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of Healthcare Engineering

Article Title: GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma

doi: 10.1155/2022/2518847

Figure Lengend Snippet: Immunohistochemical staining of tumors. (a) Tumor expressing IL-2 in the GP96 + SMP30 group; the brown cytoplasm indicates positive staining. (b) Tumor expressing IL-2 in the GP96 group; the colorless cytoplasm indicates negative staining. (c) Tumor expressing IFN- γ in the GP96 + SMP30 group; the brown cytoplasm indicates positive staining. (d) Tumor expressing IFN- γ in the SMP30 group; the colorless cytoplasm indicates negative staining.

Article Snippet: We used mouse anti-human HSP90, rabbit anti-human GP96 (Wuhan Boster Biological Technology Ltd.), and mouse anti-human SMP30 (Santa Cruz Biotechnology Inc.) antibodies.

Techniques: Immunohistochemical staining, Staining, Expressing, Negative Staining

Journal: PLoS ONE

Article Title: Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species and Membrane Localization

doi: 10.1371/journal.pone.0016545

Figure Lengend Snippet: HEK-293A cells (A) and C3A liver cells (B) were treated with the indicated number of viral particles for 72 h and the expression of SMP30-HA was analyzed by western blotting using SMP30 or HA antibodies.

Article Snippet: SMP30 antibody was supplied by Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).

Techniques: Expressing, Western Blot

Journal: PLoS ONE

Article Title: Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species and Membrane Localization

doi: 10.1371/journal.pone.0016545

Figure Lengend Snippet: Rat liver cytosolic extract in increasing amounts (10, 20 and 30 µg total protein marked as 1, 2 and 3) were subjected to western blotting using antibody against SMP30. Extracts of C3A liver cells expressed SMP30-HA was shown for comparison.

Article Snippet: SMP30 antibody was supplied by Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).

Techniques: Western Blot

Journal: PLoS ONE

Article Title: Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species and Membrane Localization

doi: 10.1371/journal.pone.0016545

Figure Lengend Snippet: The animals were injected with the control virus (Ad-null, A & B) or Ad-SMP30-HA (C & D) via the tail vein at a dose of 2×10 11 VP/animal and sacrificed on day 4 post-virus injection. Tissue homogenates were processed by western blotting using anti-HA antibody.

Article Snippet: SMP30 antibody was supplied by Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).

Techniques: Injection, Western Blot

Journal: PLoS ONE

Article Title: Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species and Membrane Localization

doi: 10.1371/journal.pone.0016545

Figure Lengend Snippet: HEK-293A cell (A) and C3A cells were treated with Ad-SMP30-HA (20 VP/cell for HEK-293A cells and 500 VP/cell for C3A liver cells) for varying periods of time, cell extracts were prepared in M-PER buffer and separated into the particulate and cytosolic fractions. Western blotting was carried out using antibody against HA tag.

Article Snippet: SMP30 antibody was supplied by Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).

Techniques: Western Blot

Journal: PLoS ONE

Article Title: Senescence Marker Protein 30 (SMP30) Expression in Eukaryotic Cells: Existence of Multiple Species and Membrane Localization

doi: 10.1371/journal.pone.0016545

Figure Lengend Snippet: A, The inhibitors, MGI32 (10 µM), PSI (50 µM), LCys (10 µM), chloroquine (50 µM) and tunicamycin (3 µg/ml) were added along with Ad-SMP30-HA (20 VP/cell) to the cells and incubated for 24 h; B, Effect of proteasomal degradation system on the processing of SMP30 protein expressed in HEK-293A cells in the presence or absence of 10 µM MG132; C, Varying concentrations of calpain inhibitor I (CI, 5, 10, 15 and 20 µM) or MDL28170 (MDL, 5, 10 and 15 µM) were added to the cells along with Ad-SMP30-HA (20 VP/cell) and incubated for 24 h; D, HEK-293A cells were treated with 20 µM caspase inhibitor I [Z-VAD(OMe)-FMK] or 5 µM β-secretase inhibitor (Z-VLL-CHO) or 5 µM γ-secretase inhibitor (Z-LLNle-CHO) or 10 µM MG132 along with Ad-SMP30-HA (20 VP/cell) for 24 h; Equal volume of DMSO served as control. The cells were harvested, lysed with SDS-PAGE buffer containing 5% β-mercaptoethanol and SDS-PAGE followed by western blotting was carried out using anti-HA antibody.

Article Snippet: SMP30 antibody was supplied by Cosmo Bio Co. (Denver, CO) and HA-probe antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).

Techniques: Incubation, SDS Page, Western Blot

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Correlation of low SMP30 level with worse overall survival in NSCLC patients. (A) Representative immunohistochemical (IHC) images for SMP30 expression in NSCLC (lung squamous cell carcinoma and lung adenocarcinoma) and adjacent noncancerous tissues. Scale bar, 200 and 20 µm (inset) respectively. (B) Statistical analysis of SMP30 expression in tumor tissue and adjacent noncancerous tissue of 341 NSCLC patients through IHC staining. (C-F) Kaplan-Meier survival analyses of high/low SMP30 expression based on tissue microarray IHC results for 341 NSCLC patients (C), 1,926 NSCLC patients in the Kaplan-Meier plotter database (D), 1,014 NSCLC patients from The Human Protein Atlas (original RNA-seq data from TCGA) (E), 152 NSCLC patients in the early clinical stages, and 189 NSCLC patients in the late clinical stages (F). (G) Statistical analysis of SMP30 expression in different clinical stages and T classifications of 341 NSCLC patients through IHC staining. SMP30, senescence marker protein 30; NSCLC, non-small cell lung cancer; TCGA, The Cancer Genome Atlas.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Immunohistochemical staining, Expressing, Immunohistochemistry, Microarray, RNA Sequencing, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Association of SMP30 expression with clinicopathologic parameters of patients with NSCLC

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Expressing

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Univariate and multivariate analyses of the correlation between clinicopathological variables for survival of patients with non-small cell lung cancer

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Expressing

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Correlation of low SMP30 level with worse overall survival in both LUAD and LUSC patients. (A,E) Kaplan-Meier survival analyses of high/low SMP30 expression in 719 LUAD patients and 524 LUSC patients, respectively, based on the Kaplan-Meier plotter database. (B-D,F-H) Kaplan-Meier survival analyses of high/low SMP30 expression in 131 LUAD patients and 210 LUSC patients based on the tissue microarray immunohistochemical results. SMP30, senescence marker protein 30; HR, hazard ratio; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Expressing, Microarray, Immunohistochemical staining, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of SMP30 overexpression on proliferative ability of A549 and H1299 cells, and tumor growth in H1299 cell tumor xenografts. (A) Relative protein levels of SMP30 in cell lines as determined by Western blot. β-actin was used as a loading control. (B) Representative Western blot results of Flag, SMP30, c-Myc and CyclinD1 in LV-SMP30 A549 and LV-SMP30 H1299 cells. (C) Growth curves of the A549 and H1299 cells. Cell viability was detected by CCK-8 assay and expressed as optical density values. (D) Representative images and results of the colony formation assay. Colonies were visualized by crystal violet staining. (E) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). (F) Representative results of tumor weight changes after subcutaneous injection of H1299 cells. Photographs show tumor xenograft morphologies in the LV-control and LV-SMP30 H1299 groups. (G) Representative Western blot results of Flag, SMP30, c-Myc and CyclinD1 in H1299 xenograft tumor tissues. β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. LV-control group. LV, lentivirus; SMP30, senescence marker protein 30.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Over Expression, Western Blot, Control, CCK-8 Assay, Colony Assay, Staining, Fluorescence, Injection, Marker

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of HDAC4 level of SMP30 overexpression both in vivo and in vitro, and effect of HDAC4 overexpression on NSCLC cell proliferation. (A) Representative Western blot results of HDAC4, HDAC5, HDAC7 and HDAC9 in LV-SMP30 A549 and LV-SMP30 H1299 cells. (B) Representative Western blot results of HDAC4, HDAC5, HDAC7 and HDAC9 in H1299 xenograft tumor tissues. (C) Relative protein levels of HDAC4 in cell lines as determined by Western blot. (D) Representative Western blot results of Flag, HDAC4, c-Myc and CyclinD1 in LV-HDAC4 A549 and LV-HDAC4 H1299 cells. (E) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (F) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. LV-control group. HDAC histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30; SD, standard deviation; NSCLC, non-small cell lung cancer.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Over Expression, In Vivo, In Vitro, Western Blot, Colony Assay, Staining, Fluorescence, Control, Histone Deacetylase Assay, Marker, Standard Deviation

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Essential requirement for HDAC4 in SMP30-mediated NSCLC cell proliferation. (A) Representative Western blot results of Flag, SMP30, HDAC4 and c-Myc and CyclinD1. (B) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (C) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). (D) Representative results for tumor weight changes after subcutaneous injection of H1299 cells. Photographs show tumor xenograft morphologies in the LV-SMP30 + LV-HDAC4 and LV-SMP30 + LV-control H1299 groups. (E) Representative Western blot results of SMP30, HDAC4, c-Myc and CyclinD1 in H1299 xenograft tumor tissues. β-actin was used as a Western blot loading control. The values below the Western blot band represent the relative gray values. All the data are shown as the mean ± SD. Student’s t-test, *, P<0.05 vs. the LV-SMP30 control group; #, P<0.05 vs. the LV-SMP30 group; &, P<0.05 vs. the LV-SMP30 control + LV-HDAC4 group. HDAC, histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30; SD, standard deviation; NSCLC, non-small cell lung cancer.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Western Blot, Colony Assay, Staining, Fluorescence, Injection, Control, Histone Deacetylase Assay, Marker, Standard Deviation

Journal: Translational Lung Cancer Research

Article Title: Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

doi: 10.21037/tlcr-21-982

Figure Lengend Snippet: Effect of pharmacologic inhibition of HDAC4 on proliferative abilities of H1299 cells. LV-control and LV-HDAC4 H1299 cells were pretreated with SAHA or TMP269 for 48 h. (A,B) Representative Western blot results of HDAC4, c-Myc, and CyclinD1. (C,D) Representative images and results of colony formation assay. Colonies were visualized by crystal violet staining. (E,F) Representative images (×20) and statistical analysis of EdU incorporation assay. The results are presented as the ratio between the number of EdU-positive cells (red fluorescence) and the total number of Hoechst 33342-stained cells (blue fluorescence). *, P<0.05 vs. the LV-control +SAHA/TMP269 0 µM group; #, P<0.05 vs. the LV-control + SAHA1.25 µM/TMP269 40 µM group; &, P<0.05 vs. the LV-HDAC4 + SAHA/TMP269 0 µM group. HDAC, histone deacetylase; LV, lentivirus; SMP30, senescence marker protein 30.

Article Snippet: SMP30 , HDAC4 and paired empty vector LVs were purchased from Genechem (Shanghai, China).

Techniques: Inhibition, Control, Western Blot, Colony Assay, Staining, Fluorescence, Histone Deacetylase Assay, Marker